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Introduced about a century ago, suramin remains a frontline
drug for the management of early-stage East African trypanoso-
miasis (sleeping sickness). Cellular entry into the causative
agent, the protozoan parasite Trypanosoma brucei, occurs
through receptor-mediated endocytosis involving the parasite’s
invariant surface glycoprotein 75 (ISG75), followed by transport
into the cytosol via a lysosomal transporter. The molecular basis
of the trypanocidal activity of suramin remains unclear, but
some evidence suggests broad, but specific, impacts on trypano-
some metabolism (i.e. polypharmacology). Here we observed
that suramin is rapidly accumulated in trypanosome cells pro-
portionally to ISG75 abundance. Although we found little evi-
dence that suramin disrupts glycolytic or glycosomal pathways,
we noted increased mitochondrial ATP production, but a net
decrease in cellular ATP levels. Metabolomics highlighted addi-
tional impacts on mitochondrial metabolism, including partial
Krebs’ cycle activation and significant accumulation of pyru-
vate, corroborated by increased expression of mitochondrial
enzymes and transporters. Significantly, the vast majority of
suramin-induced proteins were normally more abundant in the
insect forms compared with the blood stage of the parasite,
including several proteins associated with differentiation. We
conclude that suramin has multiple and complex effects on
trypanosomes, but unexpectedly partially activates mitochon-
drial ATP-generating activity. We propose that despite appar-
ent compensatory mechanisms in drug-challenged cells, the
suramin-induced collapse of cellular ATP ultimately leads to
trypanosome cell death.
Trypanosoma brucei is the causative agent of human and
animal African trypanosomiasis (HAT and AAT, respectively)
and has exerted significant impact on African economics, eco-
systems, and public health for centuries. Whereas there are
currently five drugs for HAT, their applicability depends on
disease stage and causative subspecies. Adverse toxicity, com-
plex administration, and emerging resistance all demand new
treatments (1–3). Concurrent is the agricultural impact of
T. brucei and the related species Trypanosoma congolense,
Trypanosoma equiperdum, Trypanosoma evansi, and Trypano-
soma vivax, which are major threats to livestock across sub-
Saharan Africa, much of Asia, and parts of South America (4).
The drug development pipeline for HAT is currently better
stocked than it has been for decades, with two new compounds,
fexinidazole and acoziborole (a benzoxaborole), in approval
and late stage clinical development, respectively (www.dndi.
org/diseases-projects/portfolio/scyx-7158/; Accessed date: March
12, 2019) (6). A second benzoxaborole is under development for
AAT (7). These drugs have both well-defined modes of action
and, for the benzoxaboroles, defined structure-specific activa-
tion pathways (8) together with a target in central mRNA
metabolism (9 –11). Identification of the drug target, together
with cellular entry pathways and metabolic interconversions,
is of high value for exploitation of additional chemical space,
for medicinal chemistry and for assessment of resistance
mechanisms.
Of current trypanocidal drugs, suramin is by far the oldest
and also presents the most complex genetic interaction with
trypanosomes (12). Suramin is a polysulfonated trypan blue
derivative and the negative charge prevents passive diffusion
across membranes and access to the central nervous system,
negating utility for late stage disease. The action of other drugs
is comparatively simple, with mechanisms of cell entry, activa-
tion, and likely target at least partly characterized (12, 13).
T. brucei suramin resistance has been challenging to obtain
both in the laboratory or the field beyond a few interesting
examples (14 –16), including one dependent on expression of a
specific variant surface glycoprotein, VSGSur (17, 18).
Suramin has high affinity for many proteins, including serum
albumin and low-density lipoprotein (LDL), and in vitro EC50
varies depending on the composition and concentration of
serum in the culture medium. The influence of LDL on suramin
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uptake and accumulation suggested an LDL receptor–
mediated pathway for suramin internalization (19), but demon-
stration that altering abundance of LDL-binding sites in para-
sites does not impact the EC50 suggested that this was unlikely
(20). Subsequently, the invariant surface glycoprotein ISG75
was identified as a major surface molecule involved in suramin
sensitivity, together with the lysosomal MFST for cytosolic
delivery (12, 21). Together, these data support a model for sur-
amin entry mediated by endocytosis and delivery to the lyso-
some and explain the selective sensitivity of trypanosomes.
In many organisms, suramin has complex effects, including
interactions with phosphatases (22), the cystic fibrosis chloride
channel (23), and signaling pathway components (24), as well as
acting as an immunosuppressant and chromatin modulator
through sirtuins (25). Suramin inhibits Zika virus replication
(26, 27) and has a beneficial impact on autism spectrum disor-
der (28). However, whereas many of these examples likely rep-
resent charge-mediated and nonspecific interactions between
suramin and protein, there are important and specific interac-
tions with biological systems (24, 29). The potential for suramin
repurposing into these pharmacological spaces has been damp-
ened by possible polypharmacology, toxicity, and an absence of
a clear understanding of biochemical impact in any system.
Similarly, the mechanism of suramin trypanocidal activity
remains unresolved. Whereas suramin inhibits the activity
of cytosolic pyruvate kinase (cPYK) and all seven glycolytic
enzymes compartmentalized in glycosomes (30) with IC50 val-
ues of 3–100 M (31, 32), suramin inhibits trypanosome repli-
cation at 35 nM (12), indicating that, in the absence of a mech-
anism for significant concentration, glycolytic enzymes are
unlikely to be the primary target.
Here, we analyzed the interactions of suramin with blood-
stream form (BSF) T. brucei using metabolomics, genetics, and
proteomics. We observed little impact on glycosome morphol-
ogy or composition but found that suramin induces highly spe-
cific changes to metabolism. Specifically, decreased cellular
ATP levels are accompanied by partial activation of the Krebs’
cycle and increased expression of many proteins normally
repressed in the bloodstream form.
Results
Suramin rapidly accumulates in cells proportional to ISG75
abundance
Previous work indicated that the abundant invariant surface
glycoprotein ISG75 is involved in suramin sensitivity and that
knockdown increased the EC50 3-fold (12). Manipulation of
ISG75 copy number via altering ubiquitylation efficiency also
impacts suramin sensitivity (21). As a first step to understand-
ing how suramin kills trypanosomes, we further validated the
role of ISG75 and asked whether suramin accumulates within
the cell.
Uptake of [3H]suramin was biphasic, with a rapid initial
phase over 20 min and a longer, 4-fold slower, linear phase
lasting at least 40 min (Fig. 1). Within 15 min, 0.5 pmol of
suramin accumulated, whereas in cells overexpressing ISG75,
1.3 pmol was internalized (p  0.001). Silencing reduced accu-
mulation to 0.4 pmol (p  0.05). ISG65 silencing had no signif-
icant effect on suramin uptake compared with WT cells (Fig. 1).
Assuming a cell volume of 30 m3 (33) (this study; see below)
and uniform cellular distribution, this corresponds to intracel-
lular suramin concentrations of 1.8 M in WT, 4.5 M in over-
expressers, and 1.3 M in silenced cells. As ISG75 expression
levels in overexpressing or silenced cells were 2.5- and 0.2-
fold (mRNA levels) of the parental cells, respectively (18, 34),
there is a clear correlation between suramin accumulation and
ISG75 level. This is consistent with a receptor role for ISG75 as
suggested previously (35, 36), but rapid accumulation contrasts
with the slow rate of parasite killing, with the latter requiring
hours to days and suggestive of a protracted impact on cellular
function, rather than a rapid and complete blockade to a spe-
cific and vital process.
Suramin has no major impact on glycosome morphology
In trypanosomes, most enzymes of the glycolytic pathways
are located within peroxisome-derived organelles or glyco-
somes (30). Suramin toxicity has been suggested to involve gly-
cosomal activity, as it inhibits purified glycolytic enzymes (32),
but penetration of the highly charged suramin molecule into
the glycosome of live BSF trypanosomes has not been convinc-
ingly demonstrated, leaving doubt about an ability to disrupt
trypanosomal glycolysis in vivo.
Suramin-treated cells were initially analyzed by immunoflu-
orescence microscopy and immunoblotting. We selected three
glycolytic pathway enzymes, two localized within the glyco-
some and one in the cytosol: phosphofructokinase (PFK; glyco-
some (g)) acting before the glycolytic branch point and the most
suramin-sensitive of the glycolytic enzymes (32), phosphoglyc-
erate kinase (PGK) acting after the branch point, and pyruvate
kinase (PYK) producing pyruvate in the cytosol (c). Suramin
treatment (1 EC50) did not significantly affect the abundance
of these enzymes (Fig. 2, A and B). gPFK and gPGK remain
localized to vesicular structures, typical of glycosome staining
(Fig. 2C), and following 3– 4 days of exposure to suramin, there
was no significant alteration. Similarly, there were no changes
to cPYK localization.
The number and volume of glycosomes per cell was mea-
sured by three-dimensional EM (Movie S1 and Fig. 3). Follow-
ing treatment with suramin, the median number of glycosomes
per cell increased from 61 to 73 (p  0.009, n  10 cells). Total
glycosomal volume increased from 0.81  0.22 to 1.079  0.27
m3 (p  0.024, n  10 cells). The volume of individual glyco-
somes expanded by 12% following 3 days of suramin treatment,
with a median volume of 0.0113 m3 for untreated versus
0.0127 m3 for treated cells (p  0.037). To compare individual
glycosome volumes, eight untreated and treated cells were ana-
lyzed, representing 473 and 592 glycosomes, respectively.
Despite most glycosomes retaining volumes within the range of
untreated cells, there was a small increase in exceptionally large
glycosomes in suramin-treated cells (Fig. 3). However, a signif-
icant morphological abnormality, specifically enlargement of
the flagellar pocket, was observed (Fig. 4). This so-called “Big
Eye” phenotype is likely indicating disruption to endocytosis,
possibly as a result of decreased cellular ATP levels (37). There-
fore, immunoblotting, imaging, and ultrastructural morphom-
Suramin mode of action
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etry failed to indicate substantial changes to the glycosome but
did suggest abnormalities to energy production.
Suramin perturbs mitochondrial membrane potential and ATP
levels
Treatment with suramin led to dose- and time-dependent
reductions in cellular ATP levels, becoming significant after 8 h
when the ATP level fell to 50% of untreated cells (Fig. 5A).
Further, after 2 h of incubation with 1 or 3 EC50 suramin,
mitochondrial membrane potential (MMP) decreased by 10
and 20%, respectively, attaining a 50% decrease after 8 h and
3 EC50 suramin (Fig. 5B). In BSFs, the MMP is maintained by
the reverse activity of the F1Fo-ATPase complex, which hydro-
lyzes cytosolic ATP imported into the mitochondrial lumen
(38, 39). We therefore measured the ability of suramin to affect
the ability of the F1Fo-ATPase complex to energize mitochon-
drial membranes. Untreated BSFs were used to establish the
rate of safranin O quenching by energized mitochondria in the
presence of ATP. A baseline for rapid membrane depolariza-
tion was established with oligomycin addition (Fig. 6). Oligo-
mycin led to complete mitochondrial membrane depolariza-
tion because the addition of the uncoupler SF6487 caused no
further increase in fluorescence and was indistinguishable
between suramin-treated and -untreated cells (Fig. 6). This
confirmed that ATP import and F1Fo-ATPase proton pump
activity are unaffected by suramin and that the observed
decrease in MMP most likely results from low cellular ATP
levels.
To report specifically on mitochondrial and cytosolic ATP
levels, BSFs expressing firefly luciferase fused with three C-ter-
minal v5 tags in tandem with or without an N-terminal mito-
chondrial localization signal (MLS) were generated. The pro-
portions of luciferase present in the cytosol or mitochondrion
were verified by immunoblotting (Fig. 7). Luciferin lumines-
cence indicates that suramin causes a decrease in cytosolic ATP
levels as expected but that this is concomitant with an increase
in mitochondrial ATP levels (Fig. 7, C and D, respectively).
Suramin triggers pyruvate accumulation and proline
catabolism
Global metabolomics analysis, labeling cells with [13C]glu-
cose after 24-h suramin treatment at the EC50, indicated that 85
metabolites were significantly changed in abundance (Fig. S1
and Table S1) and that several essential pathways were
Figure 1. Suramin is taken up rapidly and accumulates to high intracellular concentrations. Shown are scintillation counts from 1  107 cells incubated
in 200 nM [3H]suramin over 15 min and surface binding cold-chased. Bars, mean of three independent experiments for WT cells (wt), ISG75-overexpressing cells
(ISG75O.E.), and ISG75- and ISG65-silenced cells (ISG75RNAi and ISG65RNAi), respectively, with the S.E. (error bars) and significance intervals from Student’s
unpaired t test (*, p  0.05; ***, p  0.001) indicated. The intracellular suramin concentration was calculated using a volume of 29 m3 for T. brucei BSF (33). Inset,
suramin uptake in the presence of 250 nM suramin monitored over 1 h (red line). Suramin is taken up in two phases, a rapid initial phase over 20 min with 19.0
pmol/min (linear regression shown as a black dashed line; r2  0.97; p  0.002, nonzero slope) and a slower phase (20 – 60 min) with 4.5 pmol/min (linear
regression shown as a dark blue dashed line; r2  0.99; p  0.048, nonzero slope). Saturability of uptake was determined by incubation of cells with 250 nM
[3H]suramin in the presence of 100 M unlabeled suramin (p  0.48, zero slope) (green line).
Suramin mode of action
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impacted. Given that ATP levels and MMP were significantly
altered, analysis at 12, 21, and 29 h of suramin treatment was
performed to identify and track primary metabolic effects. Both
cells and spent culture medium were analyzed, the latter to
determine changes to uptake or secretion of specific metabo-
lites. In this second series of experiments, glucose labeling
was omitted as 13C isotope distributions were essentially
unchanged between suramin-treated and -untreated cell
extracts at 24 h, indicating no rapid severe changes to glucose
metabolism. From this data set, 48 metabolites, identified
against an authentic standard and/or by MS fragmentation pat-
tern, were identified as significantly changed in the cell extracts
(Fig. 8 and Tables S2 and S3).
Notably, levels of the oxidative stress sentinel metabolite
ribose 5-phosphate (40) were not significantly altered. Among
the most striking changes was accumulation of pyruvate (Fig.
8). Pyruvate was only slightly increased after 12 h, but this
increased nearly 5-fold after 21 h. This was highly unexpected,
as intracellular pyruvate is in the millimolar range in untreated
trypanosomes (41). Increasing pyruvate concentration by inhi-
bition or knockdown of the plasma membrane pyruvate trans-
porter TbPT is sufficient to cause cytosolic acidification and
death (41–43), as the transporter extrudes one proton per pyru-
vate as is common for other monocarboxylate transporters
(44). We tested whether overexpression of TbPT1 could pro-
tect trypanosomes from suramin toxicity but found no shift in
suramin potency (Fig. S7).
Concomitant with this increase in intracellular pyruvate,
phosphoenolpyruvate (PEP) levels dropped by 50% at 21 h,
which may suggest increased pyruvate kinase activity or, alter-
natively, pyruvate phosphate dikinase (PPDK) conversion of
Figure 2. Suramin has no significant impact on abundance or location of selected enzymes of the glycosomal pathway. A and B, steady-state levels of
PFK, PGK, and PYK were analyzed by immunoblotting at 0 (CON), 3, or 4 days post-suramin treatment (1 EC50). -tubulin was used as loading control. Graphs
represent the mean of three independent experiments, with the S.E. indicated. C, cells were treated with 1 EC50 suramin for 0 or 4 days, and the subcellular
localizations of PFK, PGK, and PYK were detected using antibodies specific to each protein. Cells were stained with 4,6-diamidino-2-phenylindole to visualize
nuclear and mitochondrial DNA. Scale bar, 2 m.
Figure 3. Suramin has minimal impact on glycosome cellular frequency.
Cells were cultured in the presence of suramin for either 0 h (top) or 72 h
(bottom). The respective distribution of glycosome volumes and for cells
treated for 72 h with suramin is shown as a bar graph. Upon treatment with
suramin, median individual glycosome volume increased from 0.0113 to
0.0127 m3 (p  0.037). Example segmentations of whole T. brucei cell are
shown for both cases. Scale bar, 2 m.
Suramin mode of action
8334 J. Biol. Chem. (2020) 295(24) 8331–8347
 by guest on June 16, 2020
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
PEP to pyruvate. Lactate levels also appear elevated, but identi-
fication of this metabolite is low-confidence (Table S2). Glyc-
erol 3-phosphate, a late glycolytic intermediate, is raised at 21 h,
as are the upstream glycolytic intermediates fructose 1,6-bis-
phosphate and fructose 6-phosphate. However, the latter
metabolite can also be produced through the pentose phos-
phate pathway (PPP) via transketolase and glycerol 3-phos-
phate from dihydroxyacetone phosphate, which itself is down-
stream of fructose 1,6-bisphosphate and fructose 6-phosphate.
Any of these interpretations would suggest increased glucose
uptake, but metabolomics evidence is insufficient to discrimi-
nate between these possibilities.
Figure 4. Suramin leads to an enlarged flagellar pocket. Cells were grown in the presence or absence of suramin (35 nM) over 4 days and analyzed by
thin-section transmission EM. Images show ultrastructure in untreated cells or suramin-treated cells after 3 or 4 days. Enlarged flagellar pockets are marked by
an asterisk. The day 3 micrograph is representative of 7 of 15 thin sections across the flagellar pocket, whereas day 4 is representative of 14 of 22 flagellar pocket
cross-sections. In untreated cells, a large pocket is observed in 2 of 63.
Figure 5. Suramin impacts both cellular ATP production and mitochondrial membrane potential. Cells were exposed to 35 nM (1 EC50) and 105 nM (3
EC50) suramin and analyzed at the indicated time points. A, the intracellular ATP concentration was measured by a bioluminescent assay with oligomycin (2
g/ml) as positive control. Values are presented as percentage versus untreated control. B, m changes were determined using the accumulation of the
fluorescent indicator dye tetramethylrhodamine ethyl ester. Valinomycin (100 nM) was used as a depolarization control. For both panels, bars show the average
and S.E. of three independent determinations, and statistical differences were determined using Student’s unpaired two-tailed t test: *, p  0.05; **, p  0.01;
***, p  0.001 relative to untreated control.
Suramin mode of action
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An early and transient change was observed in the levels of
some intracellular amino acids and Krebs’ cycle intermediates,
suggesting a primary effect (Fig. S2). This cohort includes glu-
tamate, threonine, proline, alanine, and succinate. A decrease
in serine, threonine, and glutamate is consistent with up-regu-
lation of proline and threonine catabolism. Glutamate is an
intermediate in proline degradation (45) (Fig. 9) and the ulti-
mate end product of proline catabolism is alanine, which is
excreted (46). Alanine levels were unchanged in culture super-
natants, but, by contrast, proline was decreased 10%, consis-
tent with activated proline catabolism. Notably, elevated orni-
thine levels are accompanied by elevated N-acetylputrescine,
indicative of increased putrescine, the product of ornithine de-
carboxylase and entry into the polyamine pathway.
Proteome changes induced by suramin indicate metabolic
reprogramming
Stable-isotope labeling by amino acids in culture (SILAC)
was used to compare untreated cells with cells exposed to sur-
amin at the EC50 after 1 and 2 days of exposure to provide a
kinetic context, 1 day being considered to allow proteome
changes to become significant and 2 days to capture additional
changes that may correlate with later changes to the metabo-
lome. 4019 protein groups were identified, representing 50%
of the T. brucei proteome, 2577 of which could be quantified in
two replicates (Table S4 and Fig. 10). Surprisingly, after 1 day,
the proteome was essentially unchanged (Table S4 and Fig. S3),
which indicated that significant metabolic changes precede
observable proteome alterations. However, at 2 days, signifi-
cant alterations to protein abundance were detected.
A 1.5-fold increase in the trypanosome BSF-specific hexose
transporter THT1 (47) indicates an increased glucose uptake
capacity, which was expected from the alterations in PEP/gly-
colytic intermediates. However, with the exception of a 3-fold
increase in PPDK and, to a lesser extent, those enzymes
involved in the succinate malate shunt, the abundance of pro-
teins engaged in glycolysis was unaltered (Fig. 9 and Fig. S4).
PPDK reversibly converts PEP into pyruvate in procyclic form
(PCF) cells grown in the presence of glucose, functioning in the
glycolytic direction, generating ATP in the glycosome (48).
Whereas the glycosomal content of glycolytic enzymes is glob-
ally reduced in the PCF (from 90% of the organellar protein
content in BSF to under 50% in PCF (49)), exceptionally PPDK
and succinate malate shunt enzymes have a much higher abun-
dance in PCF (50). This suggests that suramin-treated cells
might partially maintain the glycolytic ATP/ADP and NADH/
NAD ratio using PCF-like pathways. Transketolase, a central
enzyme in the nonoxidative branch of the PPP (51) with glyco-
somal and cytosolic localizations (52), increased 2.6-fold, also
consistent with the observed increases in fructose 6-phosphate
and also, indirectly, fructose 1,6-bisphosphate, and likewise
correlates with a partial induction of a PCF-like expression
profile.
Further, suramin significantly increased the abundance of
multiple mitochondrial proteins mostly associated with func-
tions in PCFs (Fig. 9 and Fig. S4). All enzymes of the Krebs’ cycle
were up-regulated between 2- and 3-fold (Table S4 and Fig. S4).
A 	4-fold increased abundance of proline dehydrogenase,
along with 2-fold up-regulation of 
1-pyrroline-5-carboxy-
late dehydrogenase, which converts -glutamate semialdehyde
into glutamate (53), together with 3-fold increased glutamate
dehydrogenase suggests increased proline catabolism, a further
feature of PCF metabolism and concordant with the metabolo-
mics findings here (53). Threonine synthase, generating threo-
nine from O-phosphohomoserine, is also up-regulated (54).
Threonine metabolism is a major source of acetyl-CoA in both
the PCF and BSF stages (55, 56), which is further converted to
acetate by a coupled ATP-generating reaction of two enzymes
(57), succinyl-CoA:3-ketoacid CoA transferase and succinyl-
CoA synthase, which are also both increased (Fig. 9 and Fig. S4).
Acetate is, upon transport to the cytosol, converted back to
acetyl-CoA by cytosolic acetyl-CoA synthetase and feeds into
lipid synthesis (58). Altogether, this suggests that mitochon-
drial activity, and in particular ATP generation pathways, is
significantly increased (Fig. 9 and Fig. S4).
Moreover, the abundance of the mitochondrial inner mem-
brane pyruvate carriers, TbMPC1 and -2, that shuttle cytosolic
pyruvate for oxidation to acetyl-CoA and possibly fuel the
Krebs’ cycle due to higher levels of citrate synthase (59), was
increased 2-fold, consistent with the rapid increase of intracel-
lular pyruvate (see below). Of 11 further carrier proteins in the
inner mitochondrial membrane detected, two were signifi-
cantly up-regulated: MCP20 (1.6-fold), a putative SAM trans-
porter (60), and MCP12 (1.8-fold), a 2-oxoglutarate/dicarboxy-
late transporter homologue (61) that transports dicarboxylates
and tricarboxylates across the mitochondrial inner membrane
(62). The up-regulation of these mitochondrial importers indi-
cates routing of substrates to mitochondrial metabolism and is
further corroboration of this effect (Fig. 9).
Proteome alterations are similar to differentiation after
suramin exposure
Significantly, a cohort of proteins associated with differenti-
ation from long slender (LS) to short stumpy (SS) forms were
Figure 6. FoF1-ATPase activity is not affected by suramin. In situ genera-
tion of the mitochondrial membrane potential in the presence of ATP in dig-
itonin-permeabilized cells untreated or pretreated with suramin for 8 h prior
to permeabilization. OLM, oligomycin (2.5 g/ml). SF6847 (250 nM) is an
uncoupler. The displayed results represent the average activities obtained
from three independent measurements.
Suramin mode of action
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detected with increased abundance, including PAD (protein
associated with differentiation) 1 and 2, which increased
	3-fold and 2-fold, respectively; PIP39 increased 3-fold
(TbPTP1-interacting protein, 39 kDa), a phosphatase that upon
phosphorylation translocates into glycosomes and promotes
the differentiation pathway (63); and protein kinases NRKA/B
(key regulators of differentiation and established markers of
BSF-SS cells) increased 2-fold (64).
The similarities between these changes and the PCF pro-
teome were fully revealed when the changes observed upon
suramin treatment were correlated with those associated with
differentiation. Proteome differences between BSF and PCF
(50) (Fig. S5) and BSF-LS and BSF-SS forms (65) (Fig. 11) were
used, where the former comparisons used monomorphic Lister
427 and the latter used the pleomorphic EATRO1125 strain. In
both cases, data in the correlation plots were elliptically distrib-
uted, with Pearson coefficients of 0.18 (BSF/PCF, 1963 pro-
teins) and 0.49 (BSF-LS/BSF-SS, 2078 proteins), respectively,
for all finite data. These Pearson coefficients, when restricted to
mitochondrial proteins only, increase to 0.33 (BSF/PCF, 241
proteins) and to 0.72 (BSF-LS/BSF-SS, 231 proteins), respec-
tively (Fig. 12). Similarly, GO term categories “glycosome” and
“transmembrane transporter activity” were enriched, whereas
GO categories such as “ribosome,” “nucleus,” and “RNA-bind-
ing” display poor correlation (Fig. 12 and Fig. S5). Notably,
enzymes associated with PCF metabolism were up-regulated,
whereas levels of those associated with BSF-LS metabolism
were unaltered (Fig. S5). This is most obvious for the glyco-
some, where glycolytic enzymes (e.g. hexokinase, glyceralde-
hyde and 3-phosphate dehydrogenase; Fig. S11) were unaf-
fected, as is the case in BSF-SS, but distinct from PCF, where
this protein cohort is dramatically down-regulated. Similarly,
levels of mitochondrial FAD-dependent glycerol-3-phosphate
dehydrogenase and alternative oxidase, the cytochrome-inde-
pendent terminal oxidase for BSF respiration (66), correlated in
suramin-treated and BSF-SS cells but are massively down-reg-
ulated in PCF cells.
In summary, prolonged suramin exposure leads to an acti-
vated mitochondrion, quite probably in response to falling cel-
lular ATP levels. It appears there may also be an attempt to
generate ATP in the glycosome via PEP metabolism. Proteome
alterations closely resemble the BSF-SS form, certainly as far as
energy metabolism and expression of differentiation-associ-
ated proteins is concerned, whereas there is no indication of
further differentiation into true PCF forms.
Discussion
Understanding mechanism of action is crucial for connect-
ing interactions between biological systems and xenobiotics.
Recent rapid progress in determining the mechanisms of action
for trypanocidal drugs currently in the clinic or moving through
development pipelines has clarified how many of these interac-
tions operate. Frequently, these advances have revealed exquis-
ite subtlety behind the provision of drug specificity (9, 12). For
suramin the mechanism for cellular entry, exploiting a trypano-
some-specific surface protein as receptor, has been proposed,
but subsequent events within the cell have remained poorly
defined (12, 21). Here, we examined multiple facets of suramin
interactions with trypanosomes to uncover significant and spe-
cific impacts on energy production, together with potential
activation of compensatory mechanisms.
Figure 7. Suramin affects levels of cytosolic and mitochondrial ATP. A and B, subcellular localization of luciferase_v5 (A) and MLS_luciferase_v5 (with
N-terminal mitochondrial localization signal) (B) was determined in BSF whole-cell lysates (WCL) and the corresponding organellar (ORG) and cytosolic (CYT)
fraction separated by digitonin extraction. Purified fractions were analyzed by Western blotting with the following antibodies: anti-luciferase, anti-mt Hsp70
(mitochondrial marker), and anti-adenosine phosphoribosyltransferase (APRT) (cytosolic marker). The relevant sizes of the protein marker are indicated on the
left. C and D, the cytosolic and mitochondrial ATP content was measured by a TECAN M200 plate reader upon the addition of luciferin to living cells. The y axis
represents the percentage of the measured light units of cells treated with suramin to BSF cells, relative to those that were not treated with suramin (0-h
treatment). The displayed results represent the average maximal signals obtained from three independent measurements. Error bars, S.E.; ****, p  0.001.
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Suramin consists of two symmetric trisulfonated naphthyla-
mine groups with six negative charges at physiological pH, and
thus once internalized, it is trapped within the cell. Uptake
through ISG75 endocytosis enables selectivity as well as rapid
accumulation (12, 21). Size-exclusion chromatograph of
[3H]suramin incubated with serum revealed promiscuous pro-
tein binding (Fig. S6), likely explaining the extraordinarily 	40-
day plasma half-life, (67), and indicating that intracellular accu-
mulation of suramin in vivo could become considerable, with
likely only a modest proportion of the compound remaining
unbound.
Suramin apparently inhibits the functions of a wide variety of
proteins (22, 24, 31, 68 –70), but, as there is no obvious struc-
tural similarity uniting these targets, a low-specificity mecha-
nism likely operates, and efficient cellular accumulation is
probably also key to efficacy. Notably, multiple cellular path-
ways are involved in suramin sensitivity in trypanosomes, and
the genetic sensitivity profile is significantly more complex than
for other trypanocidal drugs (12). Whereas suramin inhibits
isolated glycosomal enzymes in the micromolar range (32),
which are certainly attainable within (some parts of) the cell
(Fig. 1), an increase in glycolytic enzyme levels or metabolites
unique to the glycolytic pathway is not observed. However, a fall
in cytosolic ATP is substantial and significant, with a rapid
onset, and, as there is no other significant cytoplasmic ATP-
generating mechanism, argues for impediment of glycolytic
Figure 8. Metabolite changes upon suramin treatment. Heat map of selected metabolites quantified at the indicated time points in cells after suramin
treatment and nontreated controls. Colors in the scale bar (right) correspond to intensities normalized to the 0-h point.
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ATP production. However, despite a thorough interrogation of
glycolysis and glycosomal number and composition, the exact
molecular mechanism responsible for this inferred glycolytic
disruption remains elusive (see below).
Metabolomics identified increased PPP metabolites as well
as possible late glycolytic intermediates and the overproduction
of pyruvate. Significantly, the only elevated glycolytic interme-
diates are common with the PPP, and their production via this
pathway is supported by increased abundance of transketolase
and other enzymes. Thus, increased production of pyruvate is
inferred to be from PEP by gPPDK, another potential ATP-
generating route normally only active in the insect stage. An
increase in Krebs’ cycle activity is supported by proteomics and
occurs considerably later, following suramin administration,
and we suggest that the Krebs’ cycle and PPP activation are both
likely to be secondary impacts, representing an (ultimately
futile) attempt by the trypanosome to generate energy follow-
ing the collapse of cytosolic ATP. An increase in abundance of
the glucose transporter THT1 also attests to an increased draw
on glucose requirements. Regardless, from the rather diverse
impact of suramin on trypanosome metabolism, we also cannot
exclude polypharmacology as a mechanism (i.e. the inhibition
of multiple enzymes and hence metabolic pathways).
Many enzymes classically believed to be exclusively associ-
ated with procyclic metabolism are detectable in BSF cells by
high-sensitivity LC-MS/MS, albeit at low abundance (71). This
may enable rapid adaptation to multiple extravascular niches in
the host, such as cerebrospinal fluid, subcutaneous areas, and
adipose tissue, which offer nutrient opportunities distinct from
peripheral blood, or reflect the fact that most genes are not
regulated by heterochromatinization and hence differential
expression is restricted to 2 or 3 orders of magnitude. Suramin
increased expression of many of these proteins, indicating an
expression profile that has some resemblance to the procyclic
form. These changes are far removed from a complete differen-
tiation, however, and include an absence of down-regulated
glycolysis or a full mitochondrial activation. Expression of
stumpy stage transitional markers, including PAD1 and -2, is
also suggestive of a stumpy-like expression profile. The differ-
entiation to cell cycle–arrested stumpy forms has been sug-
gested as having multiple roles in enhancing transmission,
including limiting parasitemia and attuning parasites for their
new environment in the tsetse fly (72, 73). Multiple manipula-
tions of culture conditions, as well as the creation of specific
genetic lesions, invoke partial stumpy pathway activation
and/or expression of protein markers, including PAD1. Signif-
icantly, AMPK1, implicated in the initiation of this differenti-
ation process (74 –76), is up-regulated following suramin treat-
ment, and the changes observed here are consistent with
AMPK1 activation. However, whether this is cause or effect is
unclear.
To conclude, suramin has many effects on the trypanosome
cell, and many of these are likely the consequence of a central
collapse to ATP production, presumably by the glycolytic path-
way. Activation of the pentose phosphate and mitochondrial
ATP production pathways, together with changes to protein
abundance normally associated with differentiation, are possi-
ble consequences of this decrease in ATP production. Whereas
Figure 9. Suramin impact on glycosomal and mitochondrial pathways. Enzymatic steps and transport processes are represented by black arrows with
different thickness dependent on the observed abundance change of the respective protein as a result of 48-h suramin treatment (for ratio changes, see the key
on the left). The respective metabolites changes upon 29 h of suramin treatment are color-coded (white circles, not determined). Dashed lines indicate transport
processes, where the transport proteins are unknown.
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the concentration of suramin required to inhibit glycolytic
enzymes is significantly greater than that required to kill
trypanosomes, it is possible that this concentration is achieved
by cellular accumulation though endocytosis. It is also a possi-
bility that the glycolytic system, suggested to use substrate
channeling and thus to have physical interactions between the
enzymes, can be disrupted by lower levels of suramin than
required to inhibit the individual enzymes, leading to decreased
flux and hence ATP production, but without obvious changes
to protein abundance (Fig. 13). Finally, the concept of leverag-
ing induction of differentiation by pharmacological interven-
tion was proposed as a therapeutic opportunity (77, 78); ironi-
cally, suramin has likely been exploiting such a strategy for
more than a century.
Materials and methods
T. brucei brucei culturing and transfection
BSF Molteno Institute Trypanosomal antigen type (MITat)
1.2, derived from Lister strain 427, was cultured in HMI-11
complete medium (HMI-11 supplemented with 10% fetal
bovine serum non-heat-inactivated, 100 units/ml penicillin,
100 units/ml streptomycin) (79) at 37 °C with 5% CO2 in a
humid atmosphere, in culture flasks with vented caps. 2T1 cells,
a variant of Lister 427 (80), were maintained in HMI-11 com-
plete medium in the presence of phleomycin (0.5 g/ml) and
puromycin (1 g/ml). Following transfection with stem-loop
RNAi plasmids or inducible overexpression plasmids, 2T1 cells
were maintained in phleomycin (0.5 g/ml) and hygromycin
(2.5 g/ml) (80, 81). Experiments were performed following
48-h induction with tetracycline (1 g/ml). Cells were main-
tained at densities between 1  105 and 2.5  106 cells/ml. The
suramin EC50 was assessed following 3 days of TbPT1 overex-
pression. Cells were plated at 1  104 cells/ml in 96-well plates
in a 2-fold dilution series of suramin, starting from 1 M. After
3 days of growth, 20 l of resazurin (Sigma) at 125 g/ml in PBS
was added to each well and incubated for a further 6 h at 37 °C.
Fluorescence was determined using a Gemini Fluorescent Plate
Reader (Molecular Devices) with the following settings: excita-
tion, 530 nm; emission, 585 nm; filter cutoff, 570 nm. Data were
processed in Excel; nonlinear regression analysis was carried
out in GraphPad Prism using an equation for a sigmoid curve
with variable slope.
Plasmid constructs
ORF-specific RNAi fragments of 400 – 600 bp were amplified
with PCR primers designed using RNAit (82) and cloned into
pRPaiSL to generate stem-loop, “hairpin” dsRNA to induce
RNAi knockdown (80). All constructs were verified by Sanger
sequencing. ISG75 was overexpressed in pXS5ISG75HA (34).
The following primers were used to amplify the ORF of TbPT1
for cloning into pRPaTAG: 5TbPT1Pac1 (5-GCGCGCT-
TAATTAATGGTTTACCTTGTCGATGACCTTGC-3) and
Figure 10. Global proteome changes upon 48 h of suramin exposure. Shown is a volcano plot of normalized SILAC ratios, averaged from triplicate
experiments, plotted against the respective log10-transformed p values. Selected data points are annotated. For complete annotation, see Table S4. DH,
dehydrogenase; AQP, aquaporin; AA, amino acid; AATP1, amino acid transporter 1 Tb927.8.7610; AATP10, amino acid transporter 10 Tb927.4.4820; NT4,
adenosine transporter Tb927.2.6220; AAT, amino acid transporter Tb927.4.4830; JBP1, J-binding protein 1 Tb927.11.13640; PAD, protein associated with
differentiation; PIP39, PTP1-interacting protein, 39 kDa.
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3TbPT15XbaR (5-GCGCGCTCTAGACTGCTGCGCTGCT-
CCGCCACTGTG-3). Prior to introduction into trypano-
somes, pRPaiSL and pRPaTAG constructs were linearized with
AscI, and pXS5 constructs were linearized with XhoI.
Ultrastructural analysis
Bloodstream-form T. brucei strain Lister 427, exposed or not
to 35 nM suramin (1 EC50) in culture medium for 4 days, were
prepared for EM as described previously (83). Briefly, cells were
Figure 11. Correlation of proteome changes upon suramin treatment with proteome differences between BSF and PCF and BSF-LS and BS-SS.
log2-transformed abundance shifts after 48 h of suramin (35 nM) exposure were plotted against corresponding log2-transformed abundance differences
between BSF and PCF (A–C) (50) and between BSF-LS and BSF-SS (D–F) (65). Selected GO terms are indicated by color: red, mitochondrion; blue, glycosome;
green, transmembrane transporter activity. Infinite changes were omitted for clarity. The BSF-SS data are derived from the pleomorphic strain EATRO1125 (65).
DH, dehydrogenase; PPDK, pyruvate phosphate dikinase; PYK, cytosolic pyruvate kinase; gGAPDH, glycosomal glyceraldehyde 3-phosphate dehydrogenase;
PGI, phosphoglucose isomerase; HK, hexokinase; IDH, isocitrate dehydrogenase; PGKC, phosphoglycerate kinase; PFK, phosphofructokinase; ALD, aldolase;
G3PDH, mitochondrial glycerol-3-phosphate dehydrogenase; AOX, alternative oxidase; NT4, adenosine transporter Tb927.2.6220; AATP, amino acid trans-
porter; AQP, aquaporin.
Figure 12. Correlation of proteome changes upon suramin treatment with proteome differences between BSF and PCF and between BSF-LS and
BS-SS. Shown is a bar graph of Pearson coefficients from correlations of proteome changes upon suramin treatment between BSF and PCF (gray) (50) and
between BSF-LS and BSF-SS (black) for all shared, finite quantified protein groups and selected GO terms. The BSF-SS data are derived from the pleomorphic
strain EATRO1125 (65). Corresponding correlation plots are shown in Fig. 11 (BSF-SS) and Fig. S5 (PCF).
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fixed isothermally in culture with 2.5% (v/v) glutaraldehyde at
37 °C prior to harvesting by centrifugation (800  g for 15 min).
Following fixation, samples were post-fixed in 1% (w/v)
osmium tetroxide in PBS for 30 min at room temperature and
en bloc stained with 1% (w/v) aqueous uranyl acetate. Following
dehydration through an acetone series, samples were embed-
ded in epoxy resin. Ultrathin (70-nm) sections were post-
stained with 2% uranyl acetate and lead citrate and imaged on a
Tecnai G2 transmission electron microscope (FEI, Hillsboro,
OR, USA). Resin blocks were also imaged on a Zeiss Gemini/
Merlin scanning electron microscope, and serial sections were
generated using a Gatan 3view serial sectioning system. Image
resolution was 8000  8000 pixels with a pixel size of 3 nm2 and
a z-resolution of 100 nm. Initial data processing was performed
using IMOD (84).
Ten cells in G1 phase of the cell cycle were selected from each
sample. Each cell was then segmented and reconstructed using
Amira software (versions 5.3.3 to 6.1, FEI, Eindhoven, Nether-
lands) so that glycosome volume and number could be calcu-
lated (Fig. 3) along with whole-cell volume. Individual glyco-
some volumes were calculated for eight cells from both the
untreated and treated samples. Statistical comparisons of these
parameters were performed using IBM SPSS Statistics 23. Total
glycosome volumes per cell were normally distributed for each
group, and hence a t test was applied, whereas for the remaining
statistical analyses, Mann–Whitney U was the test selected, as
none of the variables assessed were normally distributed.
Protein electrophoresis and immunoblotting
Proteins were separated by electrophoresis on 12.5% SDS-
polyacrylamidegelsandthentransferredtopolyvinylidenedifluo-
ride membranes (Immobilon, Millipore) using a wet transfer
tank (Hoefer Instruments). Nonspecific binding was blocked
with TBS with 0.2% Tween 20 (TBST) supplemented with 5%
freeze-dried milk, and proteins were detected by incubation
with primary antibody diluted in TBST with 1% milk for 1 h at
room temperature. Antibodies were used at the following dilu-
tions: mouse monoclonal anti-HA (sc-7392, Santa Cruz Bio-
technology, Inc.) at 1:10,000, rabbit monoclonal anti-Myc
(7E18, Sigma) at 1:5000, mouse monoclonal anti-v5 (37-7500,
Invitrogen) at 1:1000, rabbit polyclonal anti-ISG65 and anti-
ISG75 both at 1:10,000 (from M. Carrington (University of
Cambridge, Cambridge, UK) and P. Overath (University of
Tubingen, Germany), respectively), KMX-1 anti--tubulin at
1:2000 (MAB3408, Millipore), rabbit anti-CatL at 1:1000 (85),
mouse anti-GLP-1 at 1:1000 (86), rabbit anti-PFK (Do405,
1:50,000), rabbit anti-PGK (Do425, 1:100,000), and rabbit anti-
PYK (SB953, 1:100,000) (all from P. Michels, University of Edin-
burgh, UK). Following three washes of 10 min with TBST, the
membrane was incubated in secondary antibody diluted in
TBST with 1% milk for 1 h at room temperature. Commercial
secondary anti-rabbit peroxidase-conjugated IgG (A0545,
Sigma) and anti-mouse peroxidase-conjugated IgG (A9044,
Sigma) were used, both at 1:10,000. Detection was by chemilu-
minescence with luminol (Sigma) on BioMaxMR film (Kodak).
Densitometry quantification of relative protein level was
achieved using ImageJ software (National Institutes of Health).
Immunofluorescence
Samples were prepared as described previously (87). Anti-
bodies were used at the following dilutions: mouse and rabbit
anti-HA epitope IgG (sc-57594 and sc-7392, Santa Cruz Bio-
technology) at 1:1000, mouse 9E10 anti-Myc at 1:1000 (Sigma),
rabbit anti-ISG75 (from P. Overath) at 1:1000, rabbit anti-CatL
at 1:1000 (85), and mouse anti-GLP-1 at 1:1000 (86). Rabbit
anti-PFK (Do405, 1:1000), rabbit anti-PGK (Do425, 1:1000),
and rabbit anti-PYK (SB953, 1:500) were all from P. Michels.
Secondary antibodies were used at the following dilutions: anti-
mouse Oregon Green (Molecular Probes) at 1:1000 and anti-
rabbit Cy3 (Sigma) at 1:1000. Cells were examined on a Nikon
Eclipse E600 epifluorescence microscope fitted with optically
matched filter blocks and a Hamamatsu ORCA CCD camera.
Digital images were captured using Metamorph software (Uni-
versal Imaging Corp.), and raw images were processed using
Adobe Photoshop CS3 (Adobe Systems Inc.).
Suramin uptake
Parasites from 2T1, ISG65 RNAi, ISG75 RNAi, and ISG75–
overexpressing lines were grown in HMI-11 medium supple-
mented with 10% fetal bovine serum in the presence of 1 M/ml
tetracycline for 60 h at 37 °C in humid atmosphere with 5%
CO2. Cells were then harvested by centrifugation at 1000  g
and washed twice with uptake assay buffer (33 mM HEPES, 98
mM NaCl, 4.6 mM KCl, 0.5 mM CaCl2, 0.07 mM MgSO4, 5.8 mM
NaH3PO4, 0.03 mM MgCl2, 23 mM NaHCO3, 14 mM glucose,
pH 7.3). To determine the linear phase of uptake of
[3H]suramin, 1  107 cells resuspended in uptake assay buffer
were incubated with 250 nM [3H]suramin (20 Ci/mmol; Amer-
ican Radiolabeled Chemicals) for preset times up to 60 min.
Figure 13. Schematic view of potential impact of suramin on glycolytic
complexes. There are several lines of evidence that suramin is a promiscuous
binder, and multiple diverse low-affinity targets have been described. It is
possible that suramin binding disrupts glycolytic protein complexes even at
low concentration through conformational impact (A). Due to rapid accumu-
lation of suramin by endocytic uptake, higher concentrations could be
reached, potentially resulting in complete inhibition of single (B) or multiple
protein targets (C) within a complex. All of these scenarios would ultimately
lead to a decrease in glycolytic flux and hence ATP production.
Suramin mode of action
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The saturability of uptake was determined by incubation of
cells with 250 nM [3H]suramin in the presence of 100 M unla-
beled suramin, which yielded a rate of uptake not significantly
different from zero (p 	 0.4; F-test). We observed two phases of
suramin uptake: 1) from 0 to 20 min and 2) from 20 to at least 60
min (r2 	 0.97). To compare the rates of suramin uptake for the
four cell lines and avoid any early effect caused by the internal-
ization of the drug, 1  107 cells of each cell line were incubated
with 200 nM [3H]suramin for 15 min, consistently within the
first linear phase of transport, in assay buffer only or in the
presence of 100 M unlabeled suramin. The reaction was
stopped by the addition of 400 M unlabeled suramin in uptake
assay buffer followed by immediate centrifugation through an
oil layer (88). The cell pellet was collected and lysed by the
addition of 500 l of 2% SDS solution and agitated for at least
1 h. Then 3 ml of scintillation fluid (Scintilogic U, Lablogic) was
added to each vial and left under gentle agitation (40 rpm) for
16 h, after which time vials were manually vigorously agitated,
and scintillation was measured in a 300SL (Hidex) scintillation
counter. The comparison between cell lines is based on four
independent assays in triplicate.
Determination of ATP levels
Changes in cellular ATP levels due to the exposure of
trypanosomes to suramin at 1 EC50 (35 nM) and 3 EC50 (105
nM) concentrations were monitored using the Molecular
Probes ATP Determination Kit (A22066, Invitrogen Detection
Technologies), based on the luciferin-luciferase biolumines-
cent enzymatic reaction. Bloodstream-form cell cultures of
T. brucei 2T1 were incubated with and without test compound,
and, at each predetermined incubation time, 107 cells of each
sample were transferred into a microcentrifuge tube and cen-
trifuged at 2500  g for 10 min at 4 °C. The pellet was washed
twice with 1 ml of 50 mM Tris-HCl (pH 7.4) containing 0.1 mM
DTT and resuspended in 150 l of the same buffer. The sam-
ples were incubated with digitonin (40 M) to facilitate cell
membrane permeabilization. Cells were lysed by sonication on
ice (twice for 10 s separated by 30 s), using a Soniprep 150
(MSE) at 8-m amplitude. The samples were centrifuged at
10,000  g for 10 min at 4 °C, and the supernatant was collected
and instantly frozen in liquid nitrogen and stored at 80 °C.
Oligomycin (2.0 g/ml) was used as positive control. ATP levels
were quantified using the kit above following the manufactu-
rer’s instructions. 90 l of standard reaction solution was added
to each well of a 96-well plate, and the background lumines-
cence was recorded in a FLUOstar OPTIMA fluorimeter; 10 l
of each sample was then added to each well. The plate was
incubated at 28 °C for 15 min, and the luminescence was mea-
sured, including a standard curve with an ATP concentration
ranging from 1 nM to 1 M to allow the calculation of the ATP
concentrations in each sample. The ATP content was measured
at 0, 2, 8, and 12 h of incubation with the test sample.
MMP fluorimetric detection
Changes in mitochondrial membrane potential (m) after
incubation of trypanosomes with the suramin were determined
using the indicator dye tetramethylrhodamine ethyl ester
(TMRE). Cell suspensions of T. brucei brucei 2T1 were incu-
bated at 1 EC50 (35 nM) and 3 EC50 (105 nM) concentrations
of suramin. 3  106 cells were harvested at each time point (0, 2,
4, and 8 h) after further incubation with TMRE (100 nM) for 30
min at 37 °C. The cells were transferred into a microcentrifuge
tube and centrifuged at 2500 rpm for 10 min at room tempera-
ture. The pellet was washed once in 1 ml of PBS (pH 7.4) and
resuspended in 1 ml of fresh PBS. 200 l of cell suspension was
added to each well of a 96-well black flat-bottomed plate, and
the fluorescence proportional to the amount of TMRE perme-
ated into mitochondria was recorded in a FLUOstar OPTIMA
fluorimeter. Valinomycin (Sigma–Aldrich; 100 nM) was used as
control for mitochondrial membrane depolarization.
In situ m measurement
Estimation of the 
m in situ was done spectrofluorometri-
cally using the indicating dye safranin O (Sigma, S2255). T. bru-
cei BSF cells (6  107 cells/ml) were resuspended in a reaction
buffer containing 8 mM KCl, 110 mM potassium gluconate, 10
mM NaCl, 10 mM HEPES, 10 mM K2HPO4, 0.015 mM EGTA, 0.5
mg/ml BSA (fatty acid–free), 10 mM mannitol, 1 mM MgCl2, 2
mM ATP, and 5 M safranin O, pH 7.25. The reaction was acti-
vated with digitonin (40 M), whereas oligomycin (3 M) and
SF6847 (250 nM) were injected at specific time points during the
assay. Changes in the amount of fluorescence over time were
detected on an Infinite M200 microplate reader (TECAN) (ex,
496 nm; em, 586 nm).
In vivo ATP measurement
Cytosolic and mitochondrial ATP was measured in vivo
using ATP-dependent luciferase bioluminescence. Briefly, an
equal number of BSF cells were treated with suramin at the
concentration of 1 EC50 and 3 EC50 for 0, 2, and 12 h,
washed with PBS (pH 7.4), and resuspended in HEPES-glu-
LUC buffer (20 mM HEPES, 10 mM glucose, 116 mM NaCl, 5.6
mM KCl, 8 mM MgSO4, 1.8 mM CaCl2, pH 7.4).The emission of
light was triggered by the addition of D-luciferin (50 M; Sigma,
L6882) and immediately measured on an Infinite M200 micro-
plate reader (TECAN). The cells exhibit a maximum lumines-
cence signal within 1 min after D-luciferin addition, after
which the signal decayed rapidly; the measurement was taken at
peak intensity.
Expression of luciferase-v5 or MLS_luciferase-v5luciferase
in cytosolic and mitochondrial fractions was analyzed, tested by
Western blotting using 50 M luciferin A commercial anti-v5-
antibody and antibodies recognizing the cytosolic adenosine
phosphoribosyltransferase and mitochondrial Hsp70 protein.
SILAC labeling
HMI-11 for SILAC was prepared as described previously
(21). Either normal L-arginine and L-lysine (HMI11-R0K0) or
L-arginine U-13C6 and L-lysine 4,4,5,5-2H4 (HMI11-R6K4)
(Cambridge Isotope Laboratories) were added at 120 and 240
M, respectively. Cells treated with 35 nM suramin (1 EC50)
were grown in parallel with nontreated cells, in the presence of
HMI11-R0K0 or HMI11-R6K4, respectively. Cultures in loga-
rithmic growth phase were mixed after 24 and 48 h, respec-
tively, immediately harvested by centrifugation, washed twice
with PBS containing Complete Mini Protease Inhibitor Mix-
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ture (Roche Applied Science), resuspended in Laemmli buffer
containing 1 mM DTT, and stored at 80 °C. Samples were
generated in triplicate, and one label swap was performed. Sam-
ples were sonicated, and aliquots containing 5  106 cells were
separated on a NuPAGE bis-tris 4 –12% gradient polyacryl-
amide gel (Invitrogen). The sample lane was divided into eight
slices that were excised from the Coomassie-stained gel,
destained, and then subjected to tryptic digest and reductive
alkylation. Liquid chromatography tandem MS (LC-MS/MS)
was performed by the Proteomic Facility at the University of
Dundee. The eight fractions obtained from SDS-PAGE were
subjected to LC-MS/MS on an UltiMate 3000 RSLCnano Sys-
tem (Thermo Fisher Scientific) coupled to a Q Exactive HF
Hybrid Quadrupole-Orbitrap (Thermo Fisher Scientific). The
24-h suramin treatment set were run on an Orbitrap Velos Pro
(Thermo Fisher Scientific). Mass spectra were analyzed using
MaxQuant version 1.5 (89) searching the T. brucei brucei 927
annotated protein database (release 39.0) from TriTrypDB (90).
Minimum peptide length was set at six amino acids, isoleucine
and leucine were considered indistinguishable, and false dis-
covery rates of 0.01 were calculated at the levels of peptides,
proteins, and modification sites based on the number of hits
against the reversed sequence database. SILAC ratios were cal-
culated using only peptides that could be uniquely mapped to a
given protein. When the identified peptide sequence set of one
protein contained the peptide set of another protein, these two
proteins were assigned to the same protein group. p values were
calculated, applying t test– based statistics using Perseus (91).
Proteomics data have been deposited to the ProteomeXchange
Consortium via the PRIDE partner repository (92) with the data
set identifier PXD014215.
Metabolomics
Cultures were grown and treated with 35 nM suramin in par-
allel with nontreated cells in quadruplicate. For glucose isotopic
labeling, the HMI-11 medium was supplemented with 30 mM
13C-labeled glucose. At the indicated time points (0, 12, 21, and
29 h), cultures in logarithmic growth phase were quenched by
rapid cooling to 10 °C in a dry ice/ethanol bath, and 108 cells/
sample were harvested by centrifugation (2000  g, 10 min,
4 °C). Supernatant samples were collected mixed 1:20 with
extraction solvent (chloroform/methanol/water, 1:3:1). Cells
were resuspended in 1 ml of PBS, transferred to an Eppendorf
tube, and washed once with PBS (2000  g, 10 min, 4 °C). The
pellet was resuspended in 200 l of extraction solvent, crushed
with a pipette tip, and extracted for 1 h at 4 °C under shaking
(1300 rpm). After the removal of cell debris by centrifugation
(14,000  g, 10 min, 4 °C), the extract was stored at 80 °C
under argon until LC-MS analysis. To assess instrument per-
formance, one pooled quality control sample was prepared by
mixing an equal volume of all of the samples.
LC-MS
Samples and a mixture of 240 standards (in three mixes) were
separated by HPLC on a Dionex Ultimate 3000 RSLC system
(Thermo Fisher Scientific) using a ZIC-pHILIC (Merck) col-
umn and then analyzed on a Q Exactive Orbitrap mass spec-
trometer (Thermo Fisher Scientific) using the method of Ratti-
gan et al. (93), including fragmentation of the pooled samples.
Data analysis
The standard mixes’ raw files where analyzed using ToxID
Automated Compound Screening software (Thermo Fisher
Scientific). Raw sample data files were converted to mzXML
and fragmentation files to mzML using Proteowizard (94). The
files were then uploaded into the online metabolomics platform
PiMP (95). Data were quality-controlled using the principle
component analysis (PCA) and total ion chromatograms gen-
erated by PiMP. The metabolites identified by PiMP were fil-
tered to retain only metabolites with retention times matching
standards (identified) and/or identified using fragmentation by
PiMP’s algorithm FrAnK. Double peaks were also excluded. 84
metabolites were then identified for the glucose-labeled exper-
iment and 65 for the time course experiment.
The 13C-labeled glucose experiment data set was analyzed
using mzmatch-ISO (96). The unlabeled samples were analyzed
to find significantly changed metabolites using PiMP (t test on
log-transformed data, Benjamini and Hochberg correction).
The time course data set was then analyzed by implementing a
linear model using R, followed by analysis of variance to identify
metabolites with differential time-dependent changes between
treated and untreated cells (model  lm(y  IsTreated*Time),
where y is the metabolite intensity). The 65 p values were then
corrected using the Benjamini–Hochberg procedure (false dis-
covery rate 0.05). Data for the 48 significantly changed
metabolites where then uploaded to Metaboanalyst (5) to gen-
erate a normalized heat map.
Data availability
All data (except raw ’omics data) are contained within the article.
’Omics data sets for the proteomics and metabolomics analyses are
available upon request from the corresponding author. Proteomics
data have been deposited to the ProteomeXchange Consortium via
the PRIDE partner repository (92) with the data set identifier
PXD014215.
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